Eloralintide produced 20% mean weight loss against Wegovy's 14.9% — a five-point gap, from a hormone Wegovy does not touch. But Wegovy is approved, prescribable and proven to reduce cardiovascular events, and eloralintide is none of those. The more useful framing is that these two are not competitors: they act on different receptors and can be given together.
Side by side
| Eloralintide | Wegovy | |
|---|---|---|
| Status | Investigational, phase 3 | FDA approved |
| Target | Amylin receptor | GLP-1 |
| Weight loss | 20% at 48 wks (phase 2, n=263) | 14.9% at 68 wks (phase 3, n=1,961) |
| Nausea | 33% at 9 mg | 44% |
| Fatigue | 43–46% | 11% |
| Cardiovascular indication | No | Yes, approved |
| Can you get it | No | Yes |
| Maker | Eli Lilly | Novo Nordisk |
The efficacy gap
Five percentage points is a meaningful margin — roughly five kilograms on a 100 kg starting weight. It is also the gap between a 263-person phase 2 over 48 weeks and a 1,961-person phase 3 over 68, so treat the direction as informative and the size as provisional.
What is not provisional is the mechanism. Wegovy is the reference GLP-1 drug, and eloralintide beat its figure without acting on the GLP-1 receptor at all. Whatever the final margin turns out to be, the amylin pathway is capable of results in this range on its own.
They can be combined, and that is the point
Two drugs aimed at the same receptor are alternatives. These are not. Amylin and GLP-1 are different hormones with different receptors, so the effects can add.
Novo Nordisk has already built a product on this logic: CagriSema pairs semaglutide with cagrilintide, an amylin analogue. Eli Lilly is doing the same from the other direction, with eloralintide studied alongside tirzepatide. The 20% and the 14.9% may end up being components rather than rivals.
Tolerability runs both ways
On nausea, eloralintide looks better: 33% at its top dose against Wegovy's 44%, which is the highest nausea figure among approved weight drugs.
On fatigue it is clearly worse: 43 to 46% against 11%. Nearly half the participants at the doses that produced the 20% reported it, and unlike the nausea — which appears to depend on how gently the dose is escalated — fatigue tracked the final dose. A slower climb does not obviously avoid it.
So this is a different profile rather than a better one. Details in eloralintide side effects.
What Wegovy has that no phase 2 can match
A cardiovascular indication. Wegovy is approved to reduce major cardiovascular events in adults with cardiovascular disease and overweight or obesity, on the basis of a dedicated outcomes trial. Eloralintide has no such trial published and no such approval. For anyone with established heart disease, a proven reduction in events outweighs an unproven larger weight loss.
And availability. Wegovy can be prescribed today at a known dose from a pharmacy. Eloralintide is in phase 3 and recruiting; a trial is the only legitimate route to it.
Which, and what to watch
- Treatment today: Wegovy, or another approved option — see the best GLP-1 for weight loss.
- Heart disease in the picture: Wegovy, and it is not close.
- Larger weight loss on published figures: eloralintide, from far less evidence.
- If nausea is what stopped you before: eloralintide's profile is different, but the fatigue is a real trade.
- The thing worth watching: combinations, not comparisons. Tracked in the GLP-1 pipeline tracker.
Scientific References
3 sources- 1
Billings LK, Hsia S, Bays H, et al.
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2 randomised trial
The Lancet · 406(10520) · 2025PMID: 41207310
- 2
Wilding JPH, Batterham RL, Calanna S, et al.
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1)
New England Journal of Medicine · 384(11) · 2021PMID: 33567185
NEJM - 3
Novo Nordisk
WEGOVY (semaglutide) — Prescribing Information, §6.1 Table 3
DailyMed, U.S. National Library of Medicine · 2026
NIH
References open in a new tab. Content is reviewed against peer-reviewed literature as part of our editorial policy.
About the author
Editor, Modern Weight Science
Claudiu Gheorghe is the editor of Modern Weight Science. He is not a physician. His role is to synthesize peer-reviewed studies, clinical-trial data, and FDA prescribing information into clear, plain-language explanations, and to make sure every factual claim on the site traces back to a cited source. Any decision about starting, changing, or stopping a medication belongs with a licensed clinician who knows your history.
Every claim is checked against peer-reviewed research through our review process and fact-checking policy.
Frequently Asked Questions
Is eloralintide better than Wegovy?
On published weight loss, yes: 20% at 48 weeks against 14.9% at 68 weeks. But that compares a 263-person phase 2 with a 1,961-person phase 3, so the margin is provisional. Wegovy is approved, prescribable and proven to reduce cardiovascular events, none of which eloralintide can claim.
Can eloralintide be taken with Wegovy?
In principle yes, because they target different receptors — amylin against GLP-1 — so the effects can add rather than compete. Novo Nordisk already sells this idea as CagriSema, which pairs semaglutide with an amylin analogue. Eloralintide itself is being studied with tirzepatide rather than semaglutide, and no combination results have been published.
Which has fewer side effects?
It depends which side effect. Eloralintide causes less nausea — 33% at its top dose against Wegovy's 44%, the highest among approved weight drugs. It causes far more fatigue: 43 to 46% against 11%. That is a different profile rather than a better one, and the fatigue tracked the final dose, so escalating slowly does not obviously avoid it.
Does eloralintide protect the heart like Wegovy?
Nobody knows. Wegovy carries an approved indication for reducing major cardiovascular events, earned through a dedicated outcomes trial. Eloralintide has no published cardiovascular outcomes trial and no such approval. For someone with established cardiovascular disease that is a decisive difference.
Is eloralintide a GLP-1 like Wegovy?
No. Wegovy is semaglutide, a GLP-1 receptor agonist. Eloralintide acts on the amylin receptor — a different hormone, released by the pancreas with insulin. It is routinely listed among GLP-1 drugs and it is not one, which is precisely why it can be added to one.
Continue learning
Where to read next
Not medical advice. This guide is for general education only. GLP-1 medications, dosing, and treatment suitability are decisions for you and a licensed clinician who knows your full medical history.